Get the Stockscreener App
0.5201
1.48%
-0.0078
Invivyd Inc stock is traded at $0.5201, with a volume of 1.59M.
It is down -1.48% in the last 24 hours and down -31.57% over the past month.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
See More
Previous Close:
$0.5279
Open:
$0.53
24h Volume:
1.59M
Relative Volume:
1.27
Market Cap:
$62.39M
Revenue:
-
Net Income/Loss:
$-225.14M
P/E Ratio:
-0.2654
EPS:
-1.96
Net Cash Flow:
$-192.27M
1W Performance:
-26.45%
1M Performance:
-31.57%
6M Performance:
-70.62%
1Y Performance:
-40.77%
1-Day Range:
$0.5031
$0.55
1-Week Range:
$0.483
$0.7192
52-Week Range:
$0.3546
$2.74
Invivyd Inc Stock (IVVD) Company Profile
Name
Invivyd Inc
Sector
Industry
Phone
(781) 819-0080
Address
1601 TRAPELO ROAD, WALTHAM
Compare IVVD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
0.5201 | 69.71M | 0 | -225.14M | -192.27M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-05-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-26-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-01-23 | Initiated | H.C. Wainwright | Buy |
Invivyd Inc Stock (IVVD) Latest News
Exit strategy if you’re trapped in Invivyd Inc.Gold Moves & Low Drawdown Trading Strategies - Newser
Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
Invivyd prices $50 million public offering at $0.52 per share - Investing.com
$50 Million Capital Raise: Invivyd Secures Funding for Long COVID and RSV Research Programs - Stock Titan
Invivyd prices public offering at $0.52 per share - MarketScreener
Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire Inc.
Will Invivyd Inc. stock go up soon2025 Earnings Surprises & Verified High Yield Trade Plans - Newser
Invivyd announces public offering of common stock - Investing.com
Invivyd announces proposed public offering of common stock - MarketScreener
Invivyd Announces Proposed Public Offering of Common Stock - MarketScreener
Clinical-Stage Biotech Invivyd Announces Stock Offering to Advance COVID, RSV Pipeline Programs - Stock Titan
Invivyd, Inc. Stock (IVVD) Opinions on Q2 2025 Earnings and Insider Selling - Quiver Quantitative
Trend analysis for Invivyd Inc. this weekJuly 2025 WrapUp & Free Technical Pattern Based Buy Signals - Newser
Understanding Invivyd Inc.’s price movement2025 Price Action Summary & AI Driven Price Predictions - Newser
Order flow analysis tools used on Invivyd Inc.Market Activity Recap & Long-Term Growth Portfolio Plans - Newser
How to monitor Invivyd Inc. with trend dashboardsCEO Change & Smart Swing Trading Alerts - Newser
Invivyd (IVVD) chief scientific officer Allen sells $27k in stock - Investing.com
Invivyd Inc. stock daily chart insightsJuly 2025 Highlights & Reliable Breakout Forecasts - Newser
What makes Invivyd Inc. stock price move sharplyJuly 2025 Weekly Recap & Free Community Consensus Stock Picks - beatles.ru
Invivyd Analyst Reviews: A Comprehensive Look at Ratings and Price Targets - AInvest
Invivyd Analyst Reiterates 'Buy' Rating and Price Target at $3.00 - AInvest
Invivyd: Boral Capital Raises PT to $3, Maintains Buy Rating - AInvest
Invivyd stock maintains Buy rating at H.C. Wainwright on VYD2311 path - Investing.com
What machine learning models say about Invivyd Inc.CEO Change & Low Risk High Win Rate Stock Picks - Newser
Invivyd's Breakthrough Year: Analyst Reiterates Buy Rating Amid Regulatory Advancements and Market Potential - AInvest
Retail Chatter Surges Around Invivyd After Data Show Pemgarda Neutralizes XFG COVID-19 Variant - Asianet Newsable
Invivyd’s PEMGARDA shows continued neutralizing activity against XFG variant By Investing.com - Investing.com Nigeria
Invivyd Says Pemgarda Shows Neutralizing Activity Against SARS-CoV-2 Variant XFG - MarketScreener
Invivyd’s PEMGARDA shows continued neutralizing activity against XFG variant - Investing.com
Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG ('Stratus”) - The Manila Times
Invivyd's PEMGARDA (pemivibart) Demonstrates Continued Neutralizing Activity Against Dominant SARS-CoV-2 Variant XFG and Multiple Other Circulating Variants. - AInvest
COVID Wave Rising: Invivyd's PEMGARDA Proves Effective Against New XFG "Stratus" Variant in 34 States - Stock Titan
Relief Rally in Invivyd Inc. Stock — Can It HoldJuly 2025 Spike Watch & Verified High Yield Trade Plans - metal.it
Invivyd’s Transformative Year: Regulatory Advances and Market Potential Drive Buy Rating - TipRanks
Invivyd Q2 2025 slides: Revenue growth amid missed profitability target - Investing.com
Invivyd Q2 2025 Earnings Miss Sparks Investor Concerns - AInvest
Senior Manager/Associate Director, Marketing Waltham/Bostonwill consider remo at Invivyd - Mediabistro
Invivyd Posts Q2 2025 Earnings Miss with Sustained Market Pressure - AInvest
Why is Invivyd Inc. stock going upTrade Ideas & AI Forecasted Stock Moves - thegnnews.com
Measuring Invivyd Inc.’s beta against major indicesJuly 2025 Rallies & Target Return Focused Stock Picks - Newser
Why Invivyd Inc. stock attracts strong analyst attentionJuly 2025 WrapUp & Long-Term Safe Return Strategies - Newser
Why Invivyd's Earnings Miss Masks a High-Conviction Long-Term Play in Monoclonal Antibody Innovation - AInvest
Invivyd Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Invivyd Secures FDA Approval for Streamlined Approval Pathway of COVID-19 Monoclonal Antibody VYD2311 - AInvest
Invivyd Stock: Analyst Lowers Price Target to $3.00, Maintains 'Buy' Rating - AInvest
Invivyd Inc Q2 2025 Earnings: Revenue Surges, Earnings Miss Estimates - AInvest
Pediatrix Medical Group, Inc. shares rise 2.77% intraday after Invivyd's FDA alignment for VYD2311 COVID-19 vaccine. - AInvest
Invivyd, Inc. shares fall 11.51% intraday despite FDA alignment on rapid pathway for VYD2311. - AInvest
Invivyd: Boral Capital Maintains Buy Rating, PT Down to $3 from $9 - AInvest
Alignment Healthcare shares rise 1.89% premarket after Invivyd aligns with FDA on rapid pathway for COVID-19 vaccine alternative. - AInvest
Canopy Growth Corporation shares rise 5.37% premarket after Invivyd's FDA alignment on rapid pathway for COVID-19 vaccine alternative. - AInvest
Invivyd Inc Stock (IVVD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Invivyd Inc Stock (IVVD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lee Timothy Edward | Chief Commercial Officer |
Aug 18 '25 |
Sale |
0.65 |
20,013 |
13,012 |
88,987 |
| Duke William E. | Chief Financial Officer |
Aug 19 '25 |
Sale |
0.57 |
29,643 |
16,796 |
49,344 |
| Duke William E. | Chief Financial Officer |
Aug 18 '25 |
Sale |
0.65 |
20,013 |
13,012 |
78,987 |
| Green Julie | Chief Human Resources Officer |
Aug 19 '25 |
Sale |
0.57 |
29,643 |
16,796 |
49,344 |
| Green Julie | Chief Human Resources Officer |
Aug 18 '25 |
Sale |
0.65 |
20,013 |
13,012 |
78,987 |
| Andersen Jill | Chief Legal Officer, Secretary |
Aug 19 '25 |
Sale |
0.57 |
49,402 |
27,991 |
84,446 |
| Andersen Jill | Chief Legal Officer, Secretary |
Aug 18 '25 |
Sale |
0.65 |
33,352 |
21,685 |
133,848 |
| Allen Robert D. III | Chief Scientific Officer |
Aug 19 '25 |
Sale |
0.57 |
27,420 |
15,536 |
53,068 |
| Allen Robert D. III | Chief Scientific Officer |
Aug 18 '25 |
Sale |
0.65 |
18,512 |
12,037 |
80,488 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):